LOSARTAN - Isotope Labelled Standards
References
FAQ's
References
- Carini, David John; Duncia, John Jonas Vytautas, Angiotensin II receptor blocking imidazoles, du Pont de Nemours, E. I., and Co., United States, EP253310B1, October 26, 1994
- Williams, R. C.; Alasandro, M. S.; Fasone, V. L.; Boucher, R. J.; Edwards, J. F., Comparison of liquid chromatography, capillary electrophoresis and supercritical fluid chromatography in the determination of Losartan Potassium drug substance in Cozaar tablets, Journal of Pharmaceutical and Biomedical Analysis, Volume: 14, Issue: 11, Pages: 1539-1546, 1996
Frequently Asked Questions
Can impurity control measures vary based on the intended use of Losartan?
Impurity control measures may vary depending on the dosage form and the intended use of Losartan, such as oral tablets, suspensions, or injectables. Each formulation may have its impurity limits and specifications.
How are Losartan impurities controlled during the manufacturing process?
Manufacturing processes for Losartan include stringent controls such as good manufacturing practices (GMP) and quality control measures to minimize impurities at every stage, from raw material selection to final product packaging.
Which solvent helps in analyzing Losartan impurities?
Methanol and Acetonitrile are solvents when analyzing many impurities in Losartan.
What is the recommended storage temperature for Losartan impurities?
Losartan impurities should be stored, at a controlled room temperature, usually between 2-8 °C.
Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.